Abacus dx is pleased to announce our exclusive distribution of the Streck Cell Stabilisation product range in New Zealand. Included in this product range is the Cell-Free DNA BCT, otherwise known as the “Streck Tube”.
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
Abacus dx would like to update you with the latest product from Asuragen.
For all liquid biopsies, remember to use the “Streck Tube”, the No.1 tube worldwide for stabilisation of cell free DNA.
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE[1] colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC[2].
Recent Advances and Challenges in Liquid Biopsy-Based Cancer Research
Abacus dx is happy to be able to present to you a Streck-sponsored on-demand webinar presented by Prof. Dr. med. Stefan Holdenrieder.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.